Metabolic kinetics and safety assessment of the antitumor drug meloxicam

Xinrui Jiang

doi:10.62051/1wh0jp82

Authors

Xinrui Jiang

DOI:

https://doi.org/10.62051/1wh0jp82

Keywords:

Meloxicam; Antineoplastic drug; Pharmacokinetics; Safety evaluation.

Abstract

Meloxicam is a selective cyclooxygenase-2 (COX-2) inhibitor with anti-inflammatory effects, and its anti-tumour effects have been the subject of considerable attention in recent years. This research provides a comprehensive analysis of the studies on the anti-tumour aspects of meloxicam, including the mechanism of anti-tumour action, basic pharmacokinetic studies, and an evaluation of the safety profile. The anti-tumour mechanism of meloxicam is primarily characterized by the inhibition of the COX-2/PGE2 signaling pathway, the regulation of apoptosis-related proteins, the inhibition of tumour angiogenesis and the regulation of immune function. In terms of pharmacokinetics, meloxicam has rapid oral absorption, high bioavailability and wide distribution. It is mainly metabolized by the liver, undergoing hydroxylation and oxidation to form biologically inactive metabolites. With an elimination half-life of approximately 20 hours, the safety evaluation is primarily concerned with the assessment of potential gastrointestinal, hepatic, renal and cardiovascular adverse reactions that may arise from long-term use. The application of nanotechnology has the potential to mitigate the observed toxicity).

Downloads

Download data is not yet available.

References

[1] M. P. Iturriaga, R. Paredes, J. I. Arias, et al. Meloxicam decreases the migration and invasion of CF41. Mg canine mammary carcinoma cells, Oncology Letters 14 (2) (2017) 2198 - 2206.

[2] X. Dong, R. Li, P. Xiu, et al. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2-dependent and-independent pathways, PloS one 9 (3) (2014) e92864.

[3] X. Jiang, H. Li, H. Qiao, et al. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice, Cancer science 100 (11) (2009) 2226 - 2233.

[4] T. C. Machado, A. B. Gelain, J. Rosa, et al. Cocrystallization as a novel approach to enhance the transdermal administration of meloxicam, European Journal of Pharmaceutical Sciences 123 (2018) 184 - 190.

[5] D. Coskun, O. Corum, D. D. Corum, et al. Pharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration, Veterinary Anaesthesia and Analgesia 50 (6) (2023) 477 - 484.

[6] B. Kimble, L. A. Black, K. M. Li, et al. Pharmacokinetics of meloxicam in koalas (P Phascolarctos cinereus) after intravenous, subcutaneous and oral administration, Journal of veterinary pharmacology and therapeutics 36 (5) (2013) 486 - 493.

[7] P. Lewandowska, I. Szczuka, I. Bednarz-Misa, et al. Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer, Molecules 26 (2021) 7375.

[8] J. H. Jang, S. H. Jeong, Y. B. Lee, Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model, Pharmacotherapy 43 (2) (2023) 145 - 157.

[9] A. M. Varghese, N. V. Kandra, Y. Vangoori, et al. Theophylline and meloxicam-induced Stevens-Johnson syndrome (SJS): rare case reports, Egyptian Pharmaceutical Journal 21 (4) (2022) 531 - 535.

[10] S. Junot, E. Troncy, S. Keroack, et al. Renal effect of meloxicam versus ketoprofen in anaesthetized pseudo-normovolaemic piglets, Can J Physiol Pharmacol 86 (1-2) (2008) 55 - 63.

[11] V. C. Ziesenitz, T. Welzel, M. van Dyk, et al. Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years, Paediatr Drugs 24 (6) (2022) 603-655.

[12] S. J. Keepman, M. K. A. Pellin, Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats, Journal of Feline Medicine and Surgery 24 (12) (2022) 1187 - 1194.

[13] D. Burukoglu, C. Baycu, F. Taplamacioglu, et al. Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats, Toxicology and industrial health 32 (6) (2016) 980 - 986.

[14] B. J. Gates, T. T. Nguyen, S. M. Setter, et al. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety, Expert opinion on pharmacotherapy 6 (12) (2005) 2117 - 2140.

[15] A. T. F. B. Antiorio, J. Alemán-Laporte, D. A. Zanatto, et al. Mouse behavior in the open-field test after meloxicam administration, Journal of the American Association for Laboratory Animal Science 61 (3) (2022) 270 - 274.

[16] M. Yegireddy, P. Nadoor, S. Rao, et al. Chitosan encapsulated meloxicam nanoparticles for sustained drug delivery applications: Preparation, characterization, and pharmacokinetics in Wistar rats, Molecules 27 (21) (2022) 7312.